Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange

Internal Medicine Journal

Volumn 37, Issue 5, 2007, Pages 329-332

  Chow, K V ^a   Carroll, R ^a   Branley, P ^a   Nicholls, K ^a,b   Becker, G ^a,b   Hogan, C ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anti CD20 antibody; Plasma exchange; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

ANTICONVULSIVE AGENT; IMMUNOGLOBULIN; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; EPILEPTIC STATE; FEMALE; HUMAN; HYPERTENSION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; REFRACTORY THROMBOCYTOPENIA; SINGLE DRUG DOSE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

EID: 34248375555     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01338.x     Document Type: Article

References (16)

1. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991 325: 393 7.
2. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Ann Intern Med 1995 122: 569 72.
3. Kwaan HC, Soff GA. Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997 34: 159 66.
4. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003 120: 556 73.
5. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998 339: 1579 84.
6. Tsai H. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003 14: 1072 81.
7. Tsai H, Lian EC. Antibodies to von willebrand factor-cleaving protease in acute thrombocytopenic purpura. N Engl J Med 1998 339: 1585 94.
8. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcome in a prospective cohort of 142 patients. Blood 2003 102: 60 68.
9. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A et al. Severe secondary deficiency of von Willebrand factor cleaving protease (ADAMTS13) in patients with sepsis induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006 107: 528 34.
10. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002 116: 465 7.
11. Berentsen S, Tjonnfjord GE, Brudevold R, Gjertsen BT, Langholm R, Lokkevik E. Favorable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001 115: 79 83.
12. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophoshamide and rituximab. Ann Intern Med 2003 138: 105 8.
13. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005 106: 1932 7.
14. Yomtovian R, Niklinski W, Silver B, Sarcode R, Tsai HM. Rituximab for chronic recurring thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004 124: 787 95.
15. Millward PM, Bandarenko N, Chang PP, Stagg KF, Afenyi-Annan A, Hay SN et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion 2005 45: 1481 6.
16. Galbusera M, Bresin E, Norris M, Gastoldi S, Belotti D, Capoferri C et al. Rituximab prevents the recurrence of thrombotic thrombocytopenia purpura: case report. Blood 2006 106: 925 8.